Treg Cell Therapy Pipeline — PatSnap Eureka
Regulatory T Cell Therapy Pipeline: Treg Engineering in Autoimmune Disease & Transplant Tolerance
From CAR-Treg constructs and FOXP3 transcription factor overexpression to CRISPR genome editing and nanoparticle-mediated in vivo induction — PatSnap Eureka maps the full Treg engineering landscape across autoimmunity, solid organ transplantation, and HSCT.
Treg Dysfunction Underpins Autoimmunity and Allograft Rejection
Retrieved results consistently identify the failure of immune self-tolerance — mediated by Treg dysfunction, numerical insufficiency, or phenotypic instability — as the central pathogenic event across a diverse range of conditions. These include systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), type 1 diabetes (T1D), inflammatory bowel disease (IBD), graft-versus-host disease (GvHD) following allogeneic HSCT, and solid organ transplant rejection.
The master transcription factor FOXP3 (Forkhead box protein P3) is universally cited across retrieved results as the lineage-defining marker and functional determinant of CD4+CD25+ Tregs. Helios is highlighted as a stabilizing co-transcription factor — the University of Kansas patent filing describes ectopic co-overexpression of FOXP3 and Helios as a strategy to stabilize the Treg phenotype in engineered cells.
The IL-2/IL-2R signaling axis is identified as critical for Treg homeostasis, proliferation, and suppressive function. Low-dose IL-2 administration is cited as a clinical strategy for in vivo Treg expansion in SLE patients. HLA-A2 emerges as a prominent transplant-relevant antigen target for CAR-Tregs, with demonstrated HLA-A2-specific activation and alloresponse suppression described by PatSnap Eureka sources from UCSF and King's College London.
Additional molecular targets documented across retrieved results include myelin basic protein (MBP) for CNS autoimmunity, the PD-1/PD-L1 axis for tolerogenic conditioning, CTLA-4, LAG-3, IL-10, and TGF-β as non-redundantly required effector molecules, and mTORC1 as a target to protect Tregs from granzyme B-induced apoptosis. These findings are consistent with broader immunological frameworks documented by NIH and WHO on immune tolerance mechanisms.
Nine Treg Engineering Strategies Across the Pipeline
The retrieved dataset spans clinical-stage polyclonal cell therapy through preclinical genome editing platforms, with patent analytics revealing active IP across multiple jurisdictions.
Polyclonal Treg Adoptive Cell Therapy (ACT)
Isolation, ex vivo expansion, and infusion of polyclonal CD4+CD25+FOXP3+ Tregs. GMP-grade expansion of >95% pure Tregs using CliniMACS isolation and anti-CD3/CD28 bead stimulation with IL-2 and rapamycin described by King's College Hospital. Clinical trials established for GvHD, liver transplantation (ThRIL trial), and T1D.
Phase I/II Clinical TrialsCAR-Treg Engineering
Lentiviral or retroviral transduction of Tregs with chimeric antigen receptors redirecting them toward disease-relevant antigens in an HLA-unrestricted manner. King's College London describes a CAR endodomain with JAK1/JAK2 and STAT motifs. Anti-HLA-A2 CAR-Treg platform (UCSF) employs CRISPR/Cas9 TCR deletion combined with lentiviral CAR insertion.
Preclinical / Early ClinicalTCR-Engineered Tregs
Antigen-specific Tregs generated by retroviral or CRISPR-mediated introduction of exogenous TCRs. Uniformed Services University describes TCR-Tregs specific for factor VIII (hemophilia A) and myelin antigens (MS). UCL Business Ltd. holds an active EP patent for MBP-specific TCR-Tregs for CNS autoimmune applications. Orthotopic TCR replacement (OTR) by CRISPR/Cas9 preserves near-physiological Treg function.
Preclinical / Early ClinicalFOXP3 & Transcription Factor Overexpression
Direct genome-engineering to create or stabilize Tregs via FOXP3 overexpression, sometimes combined with Helios. UCL Business Ltd. (GB) uses FOXP3-encoding polynucleotides optionally combined with TCR or CAR on a bicistronic vector. University of Kansas (EP) claims FOXP3+Helios+ engineered Tregs applied to mixed CD4+/CD8+ populations. Intellia Therapeutics discloses dmTGFB1 alongside FoxP3, Helios, and BACH2.
PreclinicalPharmacological & Cytokine-Based In Vivo Expansion
Low-dose IL-2, rapamycin (sirolimus), retinoic acid (atRA), and TGF-β1 used alone or in combination to expand Tregs in vivo or during ex vivo culture. An engineered single-chain IL-2/anti-IL-2 antibody fusion protein (F5111 immunocytokine) from Johns Hopkins selectively activates Tregs over effector cells. Low-dose IL-2 in SLE is explicitly cited as a clinical approach by Harvard Medical School.
Clinical (IL-2) / Preclinical (Fusion Proteins)Nanoparticle-Based & In Vivo Treg Programming
Nanoparticle platforms designed to generate antigen-specific Tregs in vivo by targeting APCs or delivering CRISPR/dCas9 cargo to Tregs in situ. A CRISPR/dCas9 nanocarrier (Third Military Army Medical University) upregulates TET2 in Treg cells to promote nerve regeneration and graft integration. General Nanotherapeutics describes nanoparticles engineered to switch APC support from pathogenic T cells to Tregs for SLE treatment.
PreclinicalInduced Treg (iTreg) & Tr1 Cell Engineering
Tr1 cells are characterized by CD49b+LAG-3+ co-expression and IL-10/TGF-β secretion. Stanford's pediatric stem cell group describes clinical-grade Tr1 cell generation and expansion for immune-mediated diseases. Universidad Nacional Autónoma de México describes large-scale generation of allospecific iTregs using monocyte-derived dendritic cells for transplantation applications.
Clinical Grade Protocols EstablishedPD-1/PD-L1-Based Treg Conversion & Expansion
University of Pennsylvania patent claims conversion of conventional T cells into regulatory-phenotype cells via PD-L1-expressing engineered cells activating PD-1 signaling. Northwestern University patent discloses PD-L1 conjugated to solid supports (magnetic beads) to isolate and expand Tregs, with subsequent bead removal to yield clinical-grade product.
PreclinicalKey Molecular Targets & Assignee Activity in the Treg Pipeline
Patent and literature signals extracted via PatSnap Eureka reveal concentration of IP activity at King's College London, UCL, and Miltenyi Biotec, with FOXP3 as the most-cited molecular target.
Key Molecular Targets by Citation Frequency
FOXP3 is the most frequently referenced target across all retrieved patent and literature records, followed by IL-2/CD25 and HLA-A2.
Top Assignees by Patent & Literature Presence
King's College London is the most frequently appearing assignee across both patents and papers in this dataset, with active patents in GB, SG, and CN jurisdictions.
Clinical Translation Signals by Indication
GvHD prevention post-HSCT is the most clinically advanced Treg application in this dataset, with multiple completed Phase I/II trials and established safety profiles.
Emerging Combination Engineering Strategies
Multi-payload Treg engineering strategies are converging, with CAR + IL-10 co-expression and CRISPR + CAR integration representing next-generation manufacturing approaches.
Who Is Leading the Treg Engineering IP Race?
Innovation activity is distributed across academic institutions, teaching hospitals, and biotechnology companies, with academic-institutional patent filings predominating alongside a large body of review and experimental literature.
King's College London / KCL
The most frequently appearing assignee across both patents and papers in this dataset. Active patents in GB and SG jurisdictions cover CAR-Tregs with JAK/STAT endodomains; a CN pending application extends geographic coverage. Academic output includes CAR-Treg clinical translation reviews and the HLA-A2 CAR-Treg + IL-10 co-expression study. The ThRIL liver transplant trial is associated with King's College Hospital investigators.
UCL Business Ltd. (University College London)
Holds active patents in GB and EP on FOXP3-enhanced engineered Tregs and MBP-specific TCR-Tregs, reflecting a strong IP position in both transcription factor engineering and antigen-specific TCR approaches. Academic output from UCL Division of Infection and Immunity addresses TCR/CAR specificity engineering strategies. This aligns with broader life sciences IP intelligence patterns.
Miltenyi Biotec B.V. & Co. KG
Holds an active EP patent on CAR-Tregs incorporating CD137 co-stimulatory domains, reflecting the company's positioning in both Treg manufacturing instrumentation and engineered cell product IP. Also represented in academic literature on CD137+CD154- activation signatures for stable Treg sorting.
Intellia Therapeutics, Inc.
CN pending patent on CRISPR-engineered T cells expressing double-mutant TGFβ1 (dmTGFB1) combined with multiple Treg-promoting payloads including IL-10, CTLA4, ENTPD1, NT5E, FoxP3, Helios, and BACH2. This signals aggressive genome-editing-based Treg pipeline development from a leading CRISPR-focused company.
From Bench to Bedside: Treg Therapy Clinical Milestones
GvHD prevention post-HSCT is the most clinically advanced Treg application in this dataset. Retrieved results from the University of Minnesota describe prophylactic polyclonal Treg infusion reducing severe GvHD in patients; safety profiles are established in clinical trials. Mayo Clinic (2021) confirms multiple clinical trials for polyclonal Tregs in GvHD with established safety and moderate efficacy data.
The ThRIL clinical trial at King's College Hospital explicitly proposes Treg cell therapy to induce tolerance in liver transplant recipients with a goal of drug-free transplantation — a landmark milestone for the field. This approach is supported by GMP-grade expansion protocols yielding >95% pure CD4+CD25+FOXP3+ Tregs.
For type 1 diabetes and IBD, completed or ongoing trials for Treg infusions note safety with moderate clinical benefit. Clinical trial data are described as establishing safety but requiring improved specificity and expansion strategies. Stanford's Tr1 cell clinical-grade protocols represent a parallel clinical-grade manufacturing advance.
CAR-Treg clinical translation is underway according to retrieved results from the Leibniz Institute for Immunotherapy and King's College London, building on preclinical data across multiple animal models. No Phase II/III clinical outcomes are reported in the retrieved dataset. These clinical developments are tracked by NIH and registered with WHO international clinical trial registries. Broader context on cell therapy regulatory pathways is available from the European Medicines Agency. For deeper IP analytics on clinical-stage Treg programs, PatSnap customers use Eureka to track filing activity alongside clinical trial registrations.
Combination Approaches & Emerging Directions in Treg Engineering
Retrieved results signal several convergent combination and next-generation strategies that address known limitations of single-modality Treg therapy — particularly phenotypic instability and poor in vivo persistence.
| Strategy | Key Components | Primary Challenge Addressed | Lead Source | Stage |
|---|---|---|---|---|
| CAR-Treg + Constitutive IL-10 | HLA-A2 CAR + IL-10 transgene + imaging reporter | Phenotypic instability; limited paracrine suppression | King's College London (2021) | Early Clinical |
| FOXP3 + Helios Dual TF Overexpression | FOXP3 + Helios co-expression; mixed CD4+/CD8+ populations | Ex vivo expansion instability; phenotypic drift | University of Kansas EP Patent | Preclinical |
| CRISPR/Cas9 TCR Deletion + CAR Integration | CRISPR TCR KO + lentiviral CAR or HDR into TRAC locus | TCR mispairing; competition; off-target activity | UCSF (2021) | Early Clinical |
| Allogeneic "Off-the-Shelf" Tregs | HLA class I & II matching or genetic HLA manipulation | Autologous manufacturing scalability & cost | Oxford University (2023) | Preclinical |
| mTOR Inhibition + Treg Infusion | Rapamycin analogs to block granzyme B-induced apoptosis | In vivo Treg persistence and homeostasis | Yale University | Preclinical |
Monitor Emerging Treg Engineering Patents in Real Time
PatSnap Eureka tracks new filings across CAR-Treg, FOXP3, CRISPR, and nanoparticle modalities as they publish.
Regulatory T Cell Therapy — Key Questions Answered
The most clinically advanced modality involves isolation, ex vivo expansion, and infusion of polyclonal CD4+CD25+FOXP3+ Tregs. This approach has progressed into clinical trials for GvHD, liver transplantation (the ThRIL trial at King's College London), and type 1 diabetes, with safety and feasibility established.
FOXP3 (Forkhead box protein P3) is universally cited as the lineage-defining marker and functional determinant of CD4+CD25+ Tregs. Patents from UCL Business Ltd., University of Kansas, and Lung Biotechnology PBC all claim FOXP3 overexpression as a primary mechanism for generating or stabilizing engineered Tregs.
CAR-Tregs are generated by lentiviral or retroviral transduction of regulatory T cells with chimeric antigen receptors that redirect them toward disease-relevant antigens in an HLA-unrestricted manner. Unlike conventional CAR-T cells which destroy targets, CAR-Tregs suppress alloresponses and promote immune tolerance, with applications in transplantation and autoimmune disease.
Co-overexpression with FOXP3 is specifically claimed in the University of Kansas EP patent as conferring superior Treg stability compared to FOXP3 alone, addressing the well-documented phenotypic instability of ex vivo-expanded Tregs.
Retrieved results consistently identify conditions including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), type 1 diabetes (T1D), inflammatory bowel disease (IBD), graft-versus-host disease (GvHD) following allogeneic HSCT, and solid organ transplant rejection as targets for Treg-based therapies.
Retrieved results from UCSF describe deletion of endogenous TCR by CRISPR/Cas9 combined with lentiviral CAR introduction, or site-specific CAR integration via homology-directed repair into the TRAC locus, creating mono-specific CAR Tregs. This approach eliminates TCR mispairing and competition, potentially improving both safety and efficacy.
Still have questions? Let PatSnap Eureka search the Treg patent and literature database for you.
Ask Eureka About Treg TherapiesAccelerate Your Treg Therapy Research with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map cell therapy pipelines, track competitor IP, and identify white-space opportunities in Treg engineering.
References
- Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation — King's College Hospital (2016)
- Clinical Grade Regulatory CD4+ T Cells (Tregs): Moving Toward Cellular-Based Immunomodulatory Therapies — Anthony Nolan Research Institute (2018)
- Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance — University of California, San Francisco (2021)
- Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus — Harvard Medical School (2018)
- Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection — Johns Hopkins University (2022)
- Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges — Mayo Clinic (2021)
- Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease — University of Minnesota (2022)
- Engineered T Regulatory Type 1 Cells for Clinical Application — Stanford University (2018)
- Chimeric antigen receptor-modified human regulatory T cells that constitutively express IL-10 maintain their phenotype and are potently suppressive — King's College London (2021)
- Do Treg Speed Up with CARs? Chimeric Antigen Receptor Treg Engineered to Induce Transplant Tolerance — Leibniz Institute for Immunotherapy (2022)
- Strategies to Use Nanoparticles to Generate CD4 and CD8 Regulatory T Cells for the Treatment of SLE and Other Autoimmune Diseases — General Nanotherapeutics LLC (2021)
- Large-Scale Generation of Human Allospecific Induced Tregs With Functional Stability for Use in Immunotherapy in Transplantation — Universidad Nacional Autónoma de México (2020)
- National Institutes of Health (NIH) — Immune tolerance and regulatory T cell research resources
- World Health Organization (WHO) — International clinical trial registry and immune disease frameworks
- European Medicines Agency (EMA) — Advanced therapy medicinal products (ATMP) regulatory guidance
All data, patent citations, and clinical signals on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform, PatSnap Eureka. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.